Lyell Immunopharma, Inc. reported earnings results for the first quarter ended March 31, 2024. For the first quarter, the company reported sales was USD 0.003 million compared to USD 0.065 million a year ago. Net loss was USD 60.67 million compared to USD 66.96 million a year ago.

Basic loss per share from continuing operations was USD 0.24 compared to USD 0.27 a year ago.